WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent
and Trademark Office has issued U.S. Patent No. 9,173,581. The patent
covers the core technology deployed in the DPNCheck device. The claims
cover the novel integrated design of the hand-held DPNCheck device that
enables accurate and rapid measurement of sural nerve conduction, which
is a standard neuropathy biomarker. Additional claims cover the
automation algorithms and biosensors.
This patent further establishes the leadership position of the Company
in offering easy-to-use, automated and accurate point-of-care neuropathy
testing.
About DPNCheck
DPNCheck is a quantitative nerve conduction test that is used by
physicians and health care professionals to evaluate systemic
neuropathies such as diabetic peripheral neuropathy, or DPN. It is
designed to be used at the point-of-care to objectively detect, stage,
and monitor DPN. The device measures nerve conduction velocity and
response amplitude of the sural nerve, a nerve in the lower leg and
ankle. These parameters are recognized as sensitive and specific
biomarkers of DPN.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit http://www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151120005039/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
